diagnost tool
deliv strong beat rais remain
top pick vmx tap next week pt
deliv strong beat top bottom line rais full year
guidanc well our/street estim compon rais ep
guid came tax reform fx benefit oper
nevertheless deliv anoth outstand quarter broad-bas gain
look well posit benefit meaning new product launch
geograph expans like competit win notabl refer lab year
reiter buy reiter top pick rais pt
beat us everi revenu bucket rev organ beat
beat everi revenu bucket largest beat
vs estim come lpd consumables/servic rapid test
water softwar strongest sourc growth came water
beat consumables/servic beat refer lab
beat softwar beat lpd beat
rapid assay beat instrument return growth come
adj ep beat
sedivu record unit well hand gm came
y/i invest lab oper
higher water cost princip om beat
macro environ suggest strong growth ahead report patient
practic data patient practic revenue growth y/i patient visit data
y/i view data solid consist recent survey work also agre
tax reform materi benefit tax rate guid drop
mani veterinarian small larg busi owner like benefit
reform demonstr help drive clinic revenue growth extra tax save
clinic reinvest product acceler practic revenu
rais guid rais revenue guid
vs prior vs street rais revenue guid
rep vs organ growth
rais revenue guid result fx weaker usd new revenue recognit
due asu revenu contract custom balanc
core oper similarli rais adj ep
rep fxn prior street
includ benefit tax reform fx core op
new product launch sdma-on-a-slid america week ago
taken order practic launch ou later expect
launch snap fecal antigen summer nex-gen sedivu softwar launch
neural network sedivu month
instrument place chemistri instrument america new
custom unit new vs new custom unit new abaxi
model rais rev rev
rais ep
ep
price close busi februari
global leader anim health diagnost
instrument lab servic sell direct us
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
diagnost tool
canaccord genuiti estim compani report
buy unchang target price februari
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti inc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin februari et
date time product februari et
pt use multipl adj ep y/i
pt use multipl new adj ep
price target use multipl revenu estim discount back year discount rate
pt reflect price-to-earnings multipl ep estim
risk achiev target price valuat
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
competit competit human veterinari diagnost market intens may intensifi though abaxi primari vet
marketplac current duopoli vet market abaxi compet industri titan seen rise
competit activ third largest player
buy unchang target price februari
diagnost tool
variabl order pattern guidanc abaxi busi lumpi depend pace distributor order
make forecast quarter difficult result manag chosen provid guidanc result lack
visibl may result wide rang consensu estim
econom sensit abax revenu function sell anim health clinic predominantli bill pet owner
self-pay basi macroeconomic activ employ wage home valu result chang pet owner budget
anim health industri sticki econom recess would neg impact abax busi
hska ev/rev multipl expand year ago discount idxx slight
premium abax slowdown us economi anim health util could slow revenu margin growth
particularli given industri almost self-pay small penetr health plan insur competit
abax particularli abax idexx replic strategi mirror chang distributor relationship
contribut new samsung instrument launch risk associ busi
oversea execut build ou busi consum price time new product launch abil innov
keep industri leader fewer capit resourc smaller compani risk rel competitor
oper refer lab offer product certain new product categori autom urinalysi sdma name two
thu present posit cross-sel across product well industry-lead abil maintain
expand us market share strong competitor innov introduc signific new product launch
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
